AzTrials
AzTrials

Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)SLIM-3NCT07773272

Cardiovascular-kidney-metabolic (CKM)-Guided Therapy for Patients After Acute Coronary Syndrome

An observational study of Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI) and Hypercholerolemia, run by Zuyderland Medisch Centrum at 1 site in Netherlands.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record

Search all trials

Trial summary

Patients with a history of myocardial infarction are at significantly increased risk of recurrent cardiovascular events. Despite established clinical guidelines, secondary preventive care is often initiated too late, inadequate in intensity or incomplete in application. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Rapid ESC-guideline based secondary prevention following myocardial infaction
How many people
1,215 participants
Where
1 siteNetherlands
Study dates
16 Mar 2026to 31 Mar 2029
How long will I take part?
2 Years
Phase
Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: The study population consists of patients, hospitalised in Zuyderland, who underwent a percutaneous coronary intervention due to an acute coronary syndrome (unstable angina (UA), ST-elevation myocardial infarction (STEMI), or non ST-elevation myocardial infarction (non-STEMI)).

Who may be able to join

  • Age > 18 years
  • Hospitalised with acute coronary syndrome
  • Underwent percutaneous coronary intervention

Who cannot join

  • Acute coronary syndrome secondary to other diseases
  • Life expectancy < 1 year based on the clinician's expertise

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Stan Toonen, MSc contact

+318854597522

s.toonen@zuyderland.nl

Netherlands1 site, 1 recruiting

  • Cardiology

    Heerlen, Limburg, 6419 PC

    Recruiting

Other trials in Netherlands

About this study

Patients with a history of myocardial infarction are at significantly increased risk of recurrent cardiovascular events. Despite established clinical guidelines, secondary preventive care is often initiated too late, inadequate in intensity or incomplete in application. As a result, important opportunities to prevent serious outcomes are missed.

The aim of this project is to investigate whether rapid, guideline-based treatment following myocardial infarction leads to improved patient outcomes. The study protocol is based on current clinical guidelines and targets key domains including diabetes, hypertension, and hypercholesterolemia. Outcomes of patients treated according to the study protocol will be compared to those receiving standard care. Primary endpoints include major adverse cardiac- and cerebrovascular events within a 24-month follow-up period.

The investigators hypothesize that rapid, guideline-based intervention will result in improved risk factor management, leading to a reduction in cardiovascular events and mortality. For patients, this may translate into improved health, quality of life and life expectancy. This project aims to deliver a practical protocol for effective secondary prevention in clinical practice, which is expected to reduce healthcare utilization in the long term. With this initiative, the investigators seek to take a significant step toward improving post-myocardial infarction care and contributing to sustainable cardiovascular healthcare.

Being tested
Rapid ESC-guideline based secondary prevention following myocardial infaction
Medical subject headings
Acute Coronary Syndrome, Hypertension, Diabetes Mellitus

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Rapid ESC-guideline based secondary prevention following myocardial infactionDrug

    In the intervention group, patients will be treated according to a rapid ESC-guideline-based protocol. This approach will target:

    1. Optimal pharmacological treatment, including:
    • Lipid-lowering
    • Antihypertensive
    • Diabetic, such sodium-glucose co-transporter 2 inhibitors (SGLT-2 inhibitors)
    • Glucagon-like peptide-1 agonists (GLP-1 agonists)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. MACCE within 2 years after the ACS and PCI

    The occurrence of major adverse cardiac- and cerebrovascular events (MACCE) defined as the composite of all cause death, myocardial infarction, (ischemic or hemorrhagic) CVA, and ischemia-driven revascularization at 24 months.

    Measured: From enrollment to end of 2 year follow-up

Secondary outcomes (6)

  1. 30 days endpoints checklist

    Prevelance of the following endpoints with 30 days after discharge:

    • Death due to any cause
    • Cardiovascular mortality
    • Reacurent acute coronary syndrom
    • Ischemia-driven revascularization
    • Ischemic CVA
    • Haemorrhagic CVA
    • Uplanned cardiovascular hospital readmission
    • New onset of diabetes mellitus type 2
    • New onset of peripheral arterial disease
    • Sustained decline of eGFR of 50% for more than 3 months based on eGFR lab value

    Measures will be defined as either present or absent and collected via medical record.

    Measured: From discharge till 30 days after discharge

  2. Quality of life survey at 30 days

    Patients recieve a quality of life survey at 30 days after discharge. This is done with a SF-36 questionnaire

    Measured: 30 days after discharge

  3. 1 year endpoints checklist

    Prevelance of the following endpoints 1 year after discharge:

    • Death due to any cause
    • Cardiovascular mortality
    • Reacurent acute coronary syndrom
    • Ischemia-driven revascularization
    • Ischemic CVA
    • Haemorrhagic CVA
    • Uplanned cardiovascular hospital readmission
    • New onset of diabetes mellitus type 2
    • New onset of peripheral arterial disease
    • Sustained decline of eGFR of 50% for more than 3 months

    Measures will be defined as either present or absent and collected via medical record.

    Measured: Between 30 days and 1 year after discharge

  4. Quality of life survey at 1year

    Patients recieve a quality of life survey at 1year after discharge. This is done with a SF-36 questionnaire

    Measured: 1 year after discharge

  5. 2 year endpoints checklist

    Prevelance of the following endpoints 2 years after discharge:

    • Death due to any cause
    • Cardiovascular mortality
    • Reacurent acute coronary syndrom
    • Ischemia-driven revascularization
    • Ischemic CVA
    • Haemorrhagic CVA
    • Uplanned cardiovascular hospital readmission
    • New onset of diabetes mellitus type 2
    • New onset of peripheral arterial disease
    • Sustained decline of eGFR of 50% for more than 3 months

    Measures will be defined as either present or absent and collected via medical record.

    Measured: Between 1 en 2 years after discharge

  6. Quality of life survey at 2 years

    Patients recieve a quality of life survey at 2 years after discharge. This is done with a SF-36 questionnaire

    Measured: 2 years after discharge

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Aug 2026
  2. Study start16 Mar 2026
  3. Primary completion31 Mar 2029 (estimated)
  4. Study completion31 Mar 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
1,215 participants (estimated)
Target duration
2 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT07773272
Sponsor's protocol ID
Z2025129
Acronym
SLIM-3
Status last verified
Jul 2026
First submitted
30 Jul 2026
Last updated
19 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in